13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001799883
Total reported value
$287.9M
$287.9M
21 檔
52.0%
At the close of Q4 2025, 5AM Venture Management, LLC disclosed equity holdings valued at approximately $287.9M, spread across 21 reported holdings.
5AM Venture Management, LLC executed strategic sector rebalancing during Q4 2025, establishing 1 new positions while fully exiting 5 holdings and trimming 2 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | TRDA | Entrada Therapeutics Inc | Stock-Other | 13.11% | -3.84% | -4.70% | |
| 2 | CAMP | Camp4 Therapeutics CORP | Stock-Other | 11.31% | +1.72% | — | |
| 3 | TYRA | Tyra Biosciences Inc | Stock-Other | 8.51% | +0.48% | +9.58% | |
| 4 | VRDN | Viridian Therapeutics Inc | Stock-Other | 7.21% | — | — | |
| 5 | PHVS | Pharvaris N.V. | Stock-Other | 6.96% | +3.32% | — | |
| 6 | ERAS | Erasca Inc | Stock-Other | 6.32% | -15.66% | EXIT | |
| 7 | EYPT | Eyepoint Inc | Stock-Other | 6.03% | +1.46% | — | |
| 8 | MPLT | Maplight Therapeutics Inc | Stock-Other | 5.25% | +6.47% | — | |
| 9 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 4.57% | -6.41% | EXIT | |
| 10 | CLDX | Celldex Therapeutics Inc | Stock-Other | 4.25% | +2.05% | — | |
| 11 | TECX | Tectonic Therapeutic Inc | Stock-Other | 3.98% | +2.03% | +18.57% | |
| 12 | ELVN | Enliven Therapeutics Inc | Stock-Other | 3.74% | — | — | |
| 13 | ARTV | Artiva Biotherapeutics Inc | Stock-Other | 3.17% | +3.72% | — | |
| 14 | SRZN | Surrozen Inc | Stock-Other | 2.75% | -0.69% | +25.00% | |
| 15 | BHVN | Biohaven Ltd. | Stock-Other | 2.62% | +2.08% | +54.28% | |
| 16 | TARA | Protara Therapeutic Inc | Stock-Other | 2.30% | -0.16% | +71.22% | |
| 17 | GHRS | GH Research PLC | Stock-Other | 2.29% | -2.24% | EXIT | |
| 18 | SKYE | Skye Bioscience Inc | Stock-Other | 2.28% | +0.68% | — | |
| 19 | ZNTL | Zentalis Pharmaceuticals Inc | Stock-Other | 1.68% | +4.09% | +705.70% | |
| 20 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 0.91% | +1.12% | — | |
| 21 | ✓ | Rallybio CORP | Stock-Other | 0.78% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CAMP | Camp4 Therapeutics CORP | +4.9% | — | Unchanged |
| 2 | TRDA | Entrada Therapeutics Inc | +4.1% | -4.70% | Trim |
| 3 | TYRA | Tyra Biosciences Inc | +3.7% | +9.58% | Add |
| 4 | ERAS | Erasca Inc | +2% | — | Unchanged |
| 5 | ZNTL | Zentalis Pharmaceuticals Inc | +1.4% | +705.70% | Add |
| 6 | VRDN | Viridian Therapeutics Inc | +1.4% | — | Unchanged |
| 7 | SRZN | Surrozen Inc | +1.3% | +25.00% | Add |
| 8 | TECX | Tectonic Therapeutic Inc | +1% | +18.57% | Add |
| 9 | TARA | Protara Therapeutic Inc | +1% | +71.22% | Add |
| 10 | ARTV | Artiva Biotherapeutics Inc | +0.7% | — | Unchanged |
| 11 | EYPT | Eyepoint Inc | +0.6% | — | Unchanged |
| 12 | ✓ | Rallybio CORP | +0.1% | — | Unchanged |
| 13 | SLN | Silence Therapeutics Plc-adr | — | — | Unchanged |
| 14 | BHVN | Biohaven Ltd. | 0% | +54.28% | Add |
| 15 | PHVS | Pharvaris N.V. | -0.3% | — | Unchanged |
| 16 | CLDX | Celldex Therapeutics Inc | -0.5% | — | Unchanged |
| 17 | GHRS | GH Research PLC | -0.7% | — | Unchanged |
| 18 | 260 | Centessa Pharmaceuticals-adr | -1.5% | -14.69% | Trim |
| 19 | ELVN | Enliven Therapeutics Inc | -2.1% | — | Unchanged |
| 20 | SKYE | Skye Bioscience Inc | -11.7% | — | Unchanged |
| 21 | MPLT | Maplight Therapeutics Inc | — | NEW | New buy |
| 22 | DNTH | Dianthus Therapeutics Inc | — | EXIT | Sold out |
| 23 | PRAX | Praxis Precision Medicines I | — | EXIT | Sold out |
| 24 | ALEC | Alector Inc | — | EXIT | Sold out |
| 25 | AVU0 | Adverum Biotechnologies Inc | — | EXIT | Sold out |
| 26 | MRSN | Mersana Therapeutics Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, 5AM Venture Management, LLC reported a total U.S. public equity portfolio value of $287.9M across 21 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including TRDA, CAMP, TYRA) accounted for 52.0% of total reported equity market value during Q4 2025.
Top New Position Initiated
MPLT
市值: $16.7M
Top Position Liquidated / Trimmed
DNTH
前期市值: $14.4M
During Q4 2025, 5AM Venture Management, LLC's top holdings by market value included TRDA (13.1%)、CAMP (11.3%)、TYRA (8.5%). The largest single position, TRDA, represented 13.1% of total portfolio value.
In Q4 2025, 5AM Venture Management, LLC made 14 total portfolio adjustments, initiating 1 new buys, adding to 6 positions, trimming 2 holdings, and fully liquidating 5 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.